PGL 0.00% 44.5¢ prospa group limited.

bought at 58, page-8

  1. 56,588 Posts.
    lightbulb Created with Sketch. 260
    LOL

    The ferret states:

    "PROGEN PHARMACEUTICALS (ASX:PGL), once one of the most highly
    regarded bio-techs, and once $9 a share, has been on a long, slow slide.
    Shareholders may well have believed the stock had finally hit
    rock-bottom last week at $1.125.
    But, as we have often learnt with many stocks in this shakeout,
    there's always scope for more damage.
    Progen crashed 63c to touch a new rock-bottom (no, better just
    make that "new low" for now) of 57c on Wednesday.
    It managed a recovery to 65c yesterday.
    Bio-tech followers are shocked at the sudden downturn in the
    company's fortunes, with Wednesday's stark announcement that it had
    discontinued the PI-88 phase 3 study in liver cancer.
    The company will now pursue merger and acquisition opportunities
    to expand its clinical-stage pipeline, given its strong cash position.
    Progen said that at June 30 it had $76.7 million cash, excluding
    creditors and accruals of $6.2 million.
    Hey, did it say $76.7 million?
    That's $1.26 a share.
    Hands up all Progen shareholders who would like to
    take-the-cash-and-run option."
 
watchlist Created with Sketch. Add PGL (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.